What Sylics does

Sylics is the pre-2020 identity of what now operates as InnoSer, a privately held European preclinical Contract Research Organization headquartered in Bilthoven, Netherlands, with a website that redirects from sylics.com to innoserlaboratories.com. The legal entity operates as InnoSer and serves a stated base of more than 200 pharmaceutical and biotechnology customers, including named accounts such as Roche, AstraZeneca, Daiichi Sankyo, Bayer, Bial, Agomab, Carthera, Upyther, and Montis. The company is small (11-50 employees) and privately funded, with no disclosed revenue, funding rounds, or investor information.

InnoSer's core offering is an integrated preclinical services platform covering the full discovery-to-preclinical arc: target validation, hit-to-lead, lead optimization, and preclinical drug development. Capabilities include validated in vivo mouse and rat disease models, rodent behavioral testing, histopathology and bioanalysis, colony management, and vivarium facility rental. The therapeutic footprint spans neurology (Alzheimer's, Parkinson's, ALS, Huntington's, multiple sclerosis, spinal cord injury), oncology (syngeneic, CDX, PDX, humanized, and organoid high-throughput screening models), immunology (autoimmune, inflammatory, vaccine/mRNA testing), nephrology (including the P40 adult-onset ADPKD model with longitudinal ultrasound TKV), cardiovascular (TAC, hypertension, diabetic cardiomyopathy), metabolic disease, and a deep rare disease catalog (Fragile X, Angelman, STXBP1, CMT1A, Kabuki, Phelan-McDermid, 22q11.2, and others). Differentiated technical assets include plasma and tissue biomarker panels (amyloid-beta, phosphorylated Tau, neurofilament light) and an ultrasound-mediated blood-brain barrier delivery (Sonocloud) model.

The business model is fee-for-service preclinical CRO work with custom per-study quotes, transparent upfront pricing, and multi-year contract potential. Go-to-market is sales-led and consultative, using 'Free Consultation' and 'Contact an Expert' CTAs, scientist-to-scientist engagement, dedicated study management, scientific content marketing via therapeutic-area newsletters, and conference presence. AAALAC International accreditation and a 3R's policy support regulatory and journal-publication credibility. The company maintains a Scientific Board for external scientific oversight and targets primary customer segments of Big Pharma and biotech firms needing AAALAC-accredited, customized preclinical execution across multiple therapeutic areas.

Name

Sylics

Legal name

InnoSer

Website

https://sylics.com

Company type

Private

Founded year

2020

Operating status

Operating

Headcount range

11–50 employees

Short description

Sylics, now operating as InnoSer, is a Netherlands-based preclinical contract research organization serving 200+ pharma and biotech clients with integrated in vivo disease models, behavioral testing, pathology, and bioanalysis across neurology, oncology, immunology, cardiovascular, metabolic, and rare disease programs.

Ownership category

akta.pro rank

Product category

Preclinical Contract Research Services

NAICS

Other Scientific and Technical Consulting Services (54169)

SIC

Services-Commercial Physical & Biological Research (8731)

akta.pro primary industry

Preclinical CROs (Discovery/Pharmacology/DMPK) (HLAGAAAB)

akta.pro secondary industry

Specialty Therapeutic-Area CROs (e.g., oncology/rare disease) (HLAGAAAL)

Keywords

• Preclinical CRO services
• Drug discovery research
• Animal model research
• Translational neuroscience
• Contract research organization

Headquarters

HQ city

Bilthoven

HQ country

Netherlands

HQ region

Europe

Markets served

GTM type

B2B

Offering type

Services

Cost components

Personnel, Operations, Technology or R&D, Infrastructure, Marketing or Sales

Revenue model

1. Preclinical Contract Research Services: Fee-for-service preclinical CRO engagements covering study design, execution, and data delivery across in vivo models, in vitro assays, pathology, and bioanalysis. Revenue is generated on a per-study or milestone basis with pricing described as transparent and upfront. Engagements span from discovery through preclinical development phases.

Pricing tiers

Go-to-market motion1 record

Distribution channels1 record

Marketing channels5 records

Core offering

Sylics (operating as InnoSer) is a European preclinical Contract Research Organization (CRO) providing fee-for-service drug discovery and preclinical development services. The company delivers in vivo and in vitro research using validated mouse and rodent models across therapeutic areas including neurology, oncology, immunology, nephrology, cardiovascular, metabolic, and rare diseases, with AAALAC-accredited vivarium facilities, pathology, behavioral testing, colony management, and biomarker capabilities.

Product overview

InnoSer is a European preclinical Contract Research Organization (CRO) offering a comprehensive portfolio of drug discovery and development services. The company provides an integrated service platform spanning from target validation through preclinical development, utilizing validated animal models across multiple therapeutic areas including neurology, oncology, immunology, nephrology, cardiovascular, metabolic, and rare diseases. Services include in vivo models, behavioral testing, pathology, colony management, and facility rental, supported by dedicated study management and scientist-to-scientist collaboration.

Differentiator

Problem solved

Functional benefit

Products and services

• In Vivo Models Mouse and rodent models for preclinical research across multiple therapeutic areas including oncology, neurology, immunology, and rare diseases, offered to pharmaceutical and biotech clients.
• Rodent Behavioral Testing Behavioral testing services for neurology research models assessing cognitive and motor function in rodents, used by pharma and biotech researchers.
• Pathology Services Histopathology, immunohistochemistry, and tissue analysis services supporting preclinical drug development for pharmaceutical and biotech clients.
• Colony Management Breeding, genetic validation, and cryopreservation services for genetically modified animal models, provided to preclinical research clients.
• Facility Management Vivarium rental and facility management solutions for preclinical research operations, available to pharmaceutical and biotech organizations.
• Target Validation Early discovery phase services identifying and validating novel therapeutic candidates using validated disease models for pharma and biotech clients.
• Hit-to-Lead In vitro screening and mechanism-of-action studies evaluating compound efficacy and cytotoxicity during early drug discovery for pharmaceutical clients.
• Lead Optimization PK/PD assessments and non-GLP toxicity profiling to prepare drug candidates for regulatory preclinical studies, targeting pharma R&D teams.
• Preclinical Drug Development Services Late-stage non-GLP preclinical studies including efficacy testing, dosing strategy refinement, and combination therapy studies for pharmaceutical and biotech sponsors.
• Neurology CRO Services Integrated neurology research services spanning in vitro to in vivo research, including Alzheimer's, Parkinson's, ALS, Huntington's, and Multiple Sclerosis models.
• Oncology CRO Services Comprehensive oncology services including syngeneic models, xenografts, organoid screening, and patient-derived xenografts for oncology drug development.
• Immunology CRO Services In vitro and in vivo immunology models for hypersensitivity, inflammatory, and autoimmune diseases including vaccine testing for pharmaceutical sponsors.
• Cardiovascular CRO Services Mouse models for cardiovascular diseases and heart failure (HFrEF and HFpEF) with cardiac surgery and technical procedures for cardiovascular drug discovery.
• Metabolic Disease CRO Services Gold-standard mouse models for obesity, type 2 diabetes, and associated complications including cardiac dysfunction for metabolic drug research.
• Nephrology CRO Services Kidney disease research services including ADPKD models with ultrasound-based total kidney volume assessments for renal drug development programs.
• Rare Disease Research Models Preclinical models for rare diseases including Fragile X Syndrome, Vanishing White Matter, Angelman Syndrome, Tuberous Sclerosis, and other rare neurological conditions.

Quantifiable outcome

• 200+ pharmaceutical and biotech companies served

Named customers8 records

Segments3 records

Ideal customer profiles3 records

Technology focussed No

API detail

Has API

No

API docs

API detail

Core technology

AI maturity

App detail

Feature9 records

Partnerships

13 partnerships are on record, tiered core and minor.

• Scientific Board (InnoSer)coreOthersInnoSer maintains a Scientific Board comprising recognized scientific experts who provide strategic guidance and oversight for the company's research portfolio and model development, lending credibility and scientific rigor to the CRO services.
• RocheminorGTM or Marketing PartnerRoche is listed among InnoSer's 200+ pharmaceutical and biotech customers, indicating a vendor-customer relationship for preclinical research services. No further detail on the scope of engagement is provided.
• AstraZenecaminorGTM or Marketing PartnerAstraZeneca is listed among InnoSer's 200+ pharmaceutical and biotech customers, indicating a vendor-customer relationship for preclinical research services.
• Daiichi SankyominorGTM or Marketing PartnerDaiichi Sankyo is listed among InnoSer's 200+ pharmaceutical and biotech customers, indicating a vendor-customer relationship for preclinical research services.
• BayerminorGTM or Marketing PartnerBayer is listed among InnoSer's 200+ pharmaceutical and biotech customers, indicating a vendor-customer relationship for preclinical research services.
• BialminorGTM or Marketing PartnerBial is listed among InnoSer's 200+ pharmaceutical and biotech customers, indicating a vendor-customer relationship for preclinical research services.
• AgomabminorGTM or Marketing PartnerAgomab is listed among InnoSer's biotech customers, indicating a vendor-customer relationship for preclinical research services.
• CartheraminorGTM or Marketing PartnerCarthera is listed among InnoSer's biotech customers, indicating a vendor-customer relationship for preclinical research services, potentially leveraging InnoSer's ultrasound-mediated BBB drug delivery model.
• UpytherminorGTM or Marketing PartnerUpyther is listed among InnoSer's biotech customers, indicating a vendor-customer relationship for preclinical research services.
• MontisminorGTM or Marketing PartnerMontis is listed among InnoSer's biotech customers, indicating a vendor-customer relationship for preclinical research services.
• NIN (Netherlands Institute for Neuroscience)minorStrategic or Co-development PartnerNIN is listed among InnoSer's customer/partner logos, suggesting a collaboration in neuroscience preclinical research.
• RegelminorGTM or Marketing PartnerRegel is listed among InnoSer's biotech/pharma customers or partners.
• IllimisminorGTM or Marketing PartnerIllimis is listed among InnoSer's biotech/pharma customers or partners.

Scale indicators1 record

Recent moves6 records

Expansion highlights5 records

Broad incumbents

• Eurofins Discovery: Part of Eurofins Group, this discovery services arm offers in vitro pharmacology, ADME, and in vivo services that overlap with InnoSer's preclinical testing capabilities across multiple therapeutic areas.
• Pharmaron: Integrated CRO/CDMO offering discovery, preclinical, and clinical services across multiple therapeutic areas, providing similar full preclinical value chain services to large pharma clients.
• Charles River Laboratories: Global preclinical and clinical CRO offering end-to-end discovery, safety, and manufacturing services including the RMS (Research Models and Services) segment that directly overlaps with InnoSer's in vivo model and preclinical offerings.
• Labcorp (Covance): Diversified CRO with a leading preclinical and central laboratory services franchise spanning discovery through clinical development, competing head-to-head with specialist preclinical CROs on integrated study designs.
• Wuxi AppTec: Asia-headquartered full-service CRO with significant preclinical, DMPK, and safety assessment capacity — competes with InnoSer in global pharma RFPs for integrated preclinical packages and translational biomarker studies.

Direct peers

• Sygnature Discovery: Discovery and preclinical CRO with integrated medicinal chemistry, in vitro, and in vivo pharmacology capabilities serving similar biotech and pharma clients, especially in CNS and inflammation.
• PsychoGenics: Preclinical CRO specializing in CNS/neurology rodent models, behavioral phenotyping, and drug discovery — directly comparable to InnoSer's neurology research models and behavioral testing services portfolio.
• Crown Bioscience: Oncology-focused preclinical CRO with extensive syngeneic, xenograft, PDX, and humanized model portfolios that overlap directly with InnoSer's oncology CRO services and organoid screening capabilities.
• QPS Holdings: Global CRO with strong preclinical and translational pharmacology services in CNS, metabolic, and rare disease areas, providing similar in vivo DMPK and efficacy study offerings to pharma and biotech.

Emerging players

• Biocytogen: Preclinical CRO and gene-editing specialist offering humanized mouse models and translational in vivo efficacy services, partially overlapping with InnoSer's humanized mouse and oncology offerings.

Market position

Strengths5 records

Weaknesses5 records

Competitive moat4 records

Key risks6 records

Key highlights7 records

Customer concentration

• Xx.com/InnoSer_Labs
• Facebookfacebook.com/innoserlabs
• LinkedInlinkedin.com/company/synaptologics-bv

Revenue estimate

Valuation estimate

Number of profiles

Funding overview

Funding rounds

Investors

Funding detail is available on the Subscription and Enterprise plan.Contact sales →

M&A

Investments

M&A and investment is available on the Subscription and Enterprise plan.Contact sales →

Frequently asked questions about Sylics